[go: up one dir, main page]

Haw et al., 2020 - Google Patents

TLR7 promotes smoke-induced lung damage through the activity of mast cell tryptase

Haw et al., 2020

View PDF
Document ID
3378614232304378695
Author
Haw T
Starkey M
Pavlidis S
Tam S
Nair P
Liu G
Gomez H
Hanish I
Hsu A
Kim R
Fukui R
Murakami Y
Horvat J
Foster P
Oliver B
Wark P
Adcock I
Miyake K
Sin D
Hansbro P
Publication year
Publication venue
Research Square

External Links

Snippet

Toll-like receptor (TLR) 7 is known for eliciting immunity against single-stranded RNA 35 viruses. TLR7 was increased in both human and cigarette smoke (CS)-induced 36 experimental chronic obstructive pulmonary disease (COPD). Severity of CS-induced 37 …
Continue reading at opus.lib.uts.edu.au (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00

Similar Documents

Publication Publication Date Title
Xiang et al. SARS-CoV-2 induces lymphocytopenia by promoting inflammation and decimates secondary lymphoid organs
Lu et al. Eosinophil extracellular traps drive asthma progression through neuro-immune signals
Arish et al. COVID‐19 immunopathology: from acute diseases to chronic sequelae
Sugimoto et al. IL-9 blockade suppresses silica-induced lung inflammation and fibrosis in mice
Jackson et al. The role of viruses in acute exacerbations of asthma
Willis et al. IL-17RA signaling in airway inflammation and bronchial hyperreactivity in allergic asthma
Ito et al. IL-22 induces Reg3γ and inhibits allergic inflammation in house dust mite–induced asthma models
Rotulo et al. Understanding COVID-19 in children: immune determinants and post-infection conditions
Shilovskiy et al. Modern view of neutrophilic asthma molecular mechanisms and therapy
Munitz et al. Resistin-like molecule–α regulates IL-13–induced chemokine production but not allergen-induced airway responses
US9980960B2 (en) Methods for determining the risk of cardiovascular disease in a subject having a chronic viral infection
Mebratu et al. IL-17 plays a role in respiratory syncytial virus–induced lung inflammation and emphysema in elastase and LPS-injured mice
Arikkatt et al. RAGE deficiency predisposes mice to virus-induced paucigranulocytic asthma
Mukherjee et al. STAT3-mediated IL-17 production by postseptic T cells exacerbates viral immunopathology of the lung
Liu et al. TLR7 promotes smoke-induced experimental lung damage through the activity of mast cell tryptase
Song et al. C5a receptor1 inhibition alleviates influenza virus-induced acute lung injury
Jang et al. Enhanced interferon-β response contributes to eosinophilic chronic rhinosinusitis
Killian et al. RAGE contributes to allergen driven severe neutrophilic airway inflammation via NLRP3 inflammasome activation in mice
Kawakita et al. Role of basal cells in nasal polyp epithelium in the pathophysiology of eosinophilic chronic rhinosinusitis (eCRS)
US20100247538A1 (en) IL-18 and Protein Kinase R Inhibition for the Treatment of COPD
Tang et al. Soluble E-cadherin contributes to airway inflammation in severe asthma
Vu et al. IL-1β promotes expansion of IL-33+ lung epithelial stem cells after respiratory syncytial virus infection during infancy
Haw et al. TLR7 promotes smoke-induced lung damage through the activity of mast cell tryptase
EP2700409A1 (en) IL-27 for modulation of immune response in acute lung disease
Kii et al. STAT1-mediated induction of Ly6c-expressing macrophages are involved in the pathogenesis of an acute colitis model